Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arrowhead Pharma (ARWR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,711,741
  • Shares Outstanding, K 94,207
  • Annual Sales, $ 16,140 K
  • Annual Income, $ -54,450 K
  • 60-Month Beta 2.23
  • Price/Sales 107.27
  • Price/Cash Flow N/A
  • Price/Book 10.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.22
  • Number of Estimates 5
  • High Estimate 0.33
  • Low Estimate 0.10
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +222.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.27 +5.21%
on 03/25/19
20.28 -10.40%
on 04/05/19
-0.71 (-3.76%)
since 03/18/19
3-Month
12.51 +45.24%
on 01/23/19
20.60 -11.80%
on 03/04/19
+3.65 (+25.14%)
since 01/18/19
52-Week
6.31 +187.96%
on 05/02/18
22.39 -18.85%
on 09/06/18
+11.16 (+159.20%)
since 04/18/18

Most Recent Stories

More News
Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the...

ARWR : 18.17 (-1.14%)
Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress(TM)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV), a third-generation...

ARWR : 18.17 (-1.14%)
JNJ : 137.52 (-0.72%)
Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress(TM)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress(TM) 2019 (ILC), the annual meeting of the European Association for the Study...

ARWR : 18.17 (-1.14%)
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

ABUS : 3.18 (-5.64%)
DRNA : 13.79 (+0.29%)
ARWR : 18.17 (-1.14%)
ALNY : 82.07 (-3.32%)
REGN : 333.34 (-2.81%)
MRNA : 22.51 (-4.21%)
Sangamo Therapeu has the Best Relative Performance in the Biotechnology Industry (SGMO , CHRS , STML , SPPI , ARWR)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

SGMO : 11.70 (unch)
ARWR : 18.17 (-1.14%)
STML : 12.90 (-1.75%)
CHRS : 14.71 (-0.20%)
Shares of ARWR Up 33.0% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Arrowhead Pharma (NASDAQ:ARWR) on January 8th, 2019 at $14.17. In approximately 3 months, Arrowhead Pharma has returned 33.00% as of today's recent price of $18.84....

ARWR : 18.17 (-1.14%)
Watch for Arrowhead Pharma to Potentially Pullback After Gaining 1.78% Yesterday

Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $18.55 to a high of $18.73. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high...

ARWR : 18.17 (-1.14%)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 22, 2018, the Compensation Committee of the Board...

ARWR : 18.17 (-1.14%)
Research Report Identifies Criteo S.A, Ferrari N.V, Freshpet, ServiceMaster Global, CSG Systems International, and Arrowhead Pharmaceuticals with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Criteo S.A. (NASDAQ:CRTO), Ferrari...

SERV : 49.42 (+0.73%)
FRPT : 41.91 (-0.19%)
ARWR : 18.17 (-1.14%)
CSGS : 43.81 (-1.44%)
CRTO : 21.97 (+0.32%)
RACE : 139.91 (+1.61%)
Uptrend Call Working As Arrowhead Pharma Stock Rises 34.6% (ARWR)

SmarTrend identified an Uptrend for Arrowhead Pharma (NASDAQ:ARWR) on January 8th, 2019 at $14.17. In approximately 2 months, Arrowhead Pharma has returned 34.63% as of today's recent price of $19.07....

ARWR : 18.17 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ARWR with:

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

2nd Resistance Point 19.15
1st Resistance Point 18.66
Last Price 18.17
1st Support Level 17.59
2nd Support Level 17.01

See More

52-Week High 22.39
Last Price 18.17
Fibonacci 61.8% 16.25
Fibonacci 50% 14.35
Fibonacci 38.2% 12.45
52-Week Low 6.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar